Antidepressant drug development: Focus on triple monoamine reuptake inhibition.
about
What can triumphs and tribulations from drug research in Alzheimer's disease tell us about the development of psychotropic drugs in general?Triple reuptake inhibitors as potential next-generation antidepressants: a new hope?Functional Interplay between Dopaminergic and Serotonergic Neuronal Systems during Development and Adulthood.Five potential therapeutic agents as antidepressants: a brief review and future directions.The frontal cortex as a network hub controlling mood and cognition: Probing its neurochemical substrates for improved therapy of psychiatric and neurological disorders.Refractory depression with catatonic features was remitted with administration of intravenous dopamine and consequent bupropion as maintenance treatment.
P2860
Antidepressant drug development: Focus on triple monoamine reuptake inhibition.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Antidepressant drug development: Focus on triple monoamine reuptake inhibition.
@en
type
label
Antidepressant drug development: Focus on triple monoamine reuptake inhibition.
@en
prefLabel
Antidepressant drug development: Focus on triple monoamine reuptake inhibition.
@en
P2860
P356
P1476
Antidepressant drug development: Focus on triple monoamine reuptake inhibition.
@en
P2093
Roger M Lane
P2860
P304
P356
10.1177/0269881114553252
P407
P577
2014-10-14T00:00:00Z